The extended release amantadine formulation is commonly used to treat dyskinesias in people receiving levodopa therapy for Parkinsons disease. A 2003 Cochrane review had concluded there was insufficient evidence to prove the safety or efficacy of amantadine to treat dyskinesia.In 2008, the World Health Organization reported amantadine is not effective as a stand-alone parkinsonian therapy, but recommended it could be used in combination therapy with levodopa. Influenza A
Amantadine is not recommended for treatment or prophylaxis of influenza A in the United States. Amantadine has no effect preventing or treating influenza B infections. The US Centers for Disease Control and Prevention found 100% of seasonal H3N2 and 2009 pandemic flu samples were resistant to adamantanes (amantadine and rimantadine) during the 2008–2009 flu season.The U.S. Centers for Disease Control and Prevention (CDC) guidelines recommend only neuraminidase inhibitors for influenza treatment and prophylaxis. The CDC recommends against amantadine and rimantadine to treat influenza A infections.Similarly, the 2011 World Health Organization (WHO) virology report showed all tested H1N1 influenza A viruses were resistant to amantadine. WHO guidelines recommend against use of M2 inhibitors for influenza A. The continued high rate of resistance observed in laboratory testing of influenza A has reduced the priority of M2 resistance testing.A 2014 Cochrane review did not find evidence for efficacy or safety of amantadine used for the prevention or treatment of influenza A.

Extra-pyramidal side effects
An extended release formulation is used to treat levodopa-induced dyskinesia in patients with Parkinsons disease.
This pain is often similar to pain from organic dental disease such as periapical periodontitis, or pulpitis (toothache), but unlike normal dental pain, it is not relieved in the long term by dental treatments such as endodontic therapy (root canal treatment) or tooth extraction, and it may even be worsened, return soon after, or simply migrate to other areas in the mouth following dental treatment. Definitions
Atypical facial pain
There is no universally accepted definition of AFP, and it is defined less by what it is as what it is not. Various definitions of AFP include:

"a nonmuscular or joint pain that has no detectable neurologic cause." "a condition characterized by the absence of other diagnoses and causing continuous, variable-intensity, migrating, nagging, deep, and diffuse pain." "a continuous unilateral deep aching pain sometimes with a burning component." "facial pain not fulfilling other criteria" (previous IHS definition, which now uses the term "Persistent idiopathic facial pain", see below). "persistent pain in the maxillofacial region that does not fit the diagnostic criteria of any other orofacial pain and has no identifiable cause." (Neville et al.) Atypical odontalgia
There are no globally accepted definitions of AO, but some suggested definitions are listed below:

"continuous pain in the teeth or in a tooth socket after extraction in the absence of any identifiable dental cause," (International headache society, description included as a side note of "persistent idiopathic facial pain" in the ICHD-2, i.e. with is no separate diagnosis for atypical odontalgia).